• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 57Mixed-treatment comparison – MMSE at 24–26 weeks (mean change from baseline; all measurement populations): results

TechnologyVs placeboProbability most effective
Effect95% CIProbability more effective than placebo
Placebo0.000
Donepezil1.2350.747 to 1.7781.0000.670
Galantamine
Rivastigmine1.0730.358 to 1.8090.9930.330
Memantine

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.